VTRS
Viatris Inc. NASDAQ Listed Mar 17, 1980$17.39
Mkt Cap $20.2B
52w Low $8.19
99.4% of range
52w High $17.45
50d MA $14.20
200d MA $11.99
P/E (TTM)
-5.0x
EV/EBITDA
-70.6x
P/B
1.2x
Debt/Equity
1.0x
ROE
84.1%
P/FCF
7.5x
RSI (14)
—
ATR (14)
—
Beta
0.82
50d MA
$14.20
200d MA
$11.99
Avg Volume
10.6M
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
1000 Mylan Boulevard · Canonsburg, PA 15317 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | TNS | 0.52 | 0.59 | +13.5% | — | — | — | — | — | — | — | — |
| Feb 26, 2026 | TNS | 0.53 | 0.57 | +7.1% | 15.25 | -0.6% | -2.1% | +3.0% | -2.4% | -3.5% | -4.7% | — |
| Nov 6, 2025 | TNS | 0.62 | 0.67 | +7.9% | 10.11 | -0.2% | +0.1% | +0.6% | +10.8% | +8.9% | +7.9% | — |
| Aug 7, 2025 | TNS | 0.56 | 0.62 | +11.5% | 9.39 | -0.1% | +3.3% | +5.0% | +7.8% | +10.9% | +13.8% | — |
| May 8, 2025 | TNS | 0.49 | 0.50 | +1.6% | 9.09 | -0.8% | -3.5% | -1.4% | -3.3% | -7.4% | -3.3% | — |
| Feb 27, 2025 | TNS | 0.61 | 0.54 | -11.5% | 9.53 | +1.0% | -3.1% | -2.1% | -1.7% | -0.5% | -0.2% | — |
| Nov 7, 2024 | TNS | 0.68 | 0.75 | +10.8% | 13.18 | -0.8% | -1.7% | -0.7% | -1.9% | -1.4% | -4.2% | — |
| Aug 8, 2024 | TNS | 0.68 | 0.69 | +1.8% | 12.10 | -0.2% | -2.6% | -4.4% | -4.4% | -5.8% | -3.6% | — |
| May 9, 2024 | TNS | 0.67 | 0.67 | -0.4% | 11.22 | -0.3% | -0.5% | +1.2% | -0.7% | -1.3% | -1.8% | — |
| Feb 28, 2024 | TNS | 0.67 | 0.61 | -9.0% | 12.29 | +0.6% | +0.7% | +2.4% | +0.6% | -0.1% | -0.7% | — |
| Nov 7, 2023 | TNS | 0.74 | 0.78 | +5.4% | 9.13 | +4.1% | +1.0% | -0.8% | +0.8% | -2.0% | +1.0% | — |
| Aug 7, 2023 | TNS | 0.71 | 0.75 | +5.6% | 11.00 | -0.3% | +1.4% | +2.4% | +1.5% | +3.2% | +1.7% | — |
| May 8, 2023 | AMC | 0.69 | 0.78 | +13.0% | 9.82 | -0.8% | -0.8% | -2.3% | -4.7% | -5.5% | -4.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | Barclays | Maintains | Overweight → Overweight | — | $13.29 | $13.21 | -0.6% | +0.5% | +1.6% | +0.6% | -1.8% | -2.5% |
| Jan 28 | Piper Sandler | Maintains | Neutral → Neutral | — | $13.12 | $13.15 | +0.2% | -1.1% | -0.4% | -0.2% | +4.3% | +4.3% |
| Jan 16 | Argus | Upgrade | Hold → Buy | — | $12.84 | $13.05 | +1.6% | +0.2% | -1.4% | +1.6% | +3.1% | +2.9% |
| Mar 7 | Jefferies | Maintains | Buy → Buy | — | $9.51 | $9.51 | +0.0% | +1.5% | -0.1% | -1.8% | -2.8% | -5.6% |
| Mar 5 | Piper Sandler | Maintains | Neutral → Neutral | — | $9.37 | $9.35 | -0.2% | +1.2% | +1.5% | +3.0% | +1.4% | -0.3% |
| Feb 28 | Barclays | Maintains | Underweight → Underweight | — | $9.53 | $9.63 | +1.0% | -3.1% | -2.1% | -1.7% | -0.5% | -0.2% |
| Feb 28 | BofA Securities | Maintains | Underperform → Underperform | — | $9.53 | $9.63 | +1.0% | -3.1% | -2.1% | -1.7% | -0.5% | -0.2% |
| Dec 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $12.89 | $12.97 | +0.6% | -1.3% | -0.7% | -2.9% | -1.1% | -0.5% |
| Nov 8 | Barclays | Maintains | Underweight → Underweight | — | $13.18 | $13.07 | -0.8% | -1.7% | -0.7% | -1.9% | -1.4% | -4.2% |
| Mar 28 | Piper Sandler | Maintains | Neutral → Neutral | — | $11.83 | $11.81 | -0.2% | +0.9% | +0.9% | +0.9% | +1.6% | -0.6% |
| Nov 22 | Piper Sandler | Maintains | Neutral → Neutral | — | $9.38 | $9.36 | -0.2% | -0.1% | +0.5% | -0.4% | -2.6% | -2.7% |
| Oct 23 | BofA Securities | Downgrade | Neutral → Underperform | — | $9.30 | $9.01 | -3.1% | -4.1% | -2.0% | -3.5% | -3.3% | -5.7% |
| Jun 23 | Barclays | Downgrade | Equal Weight → Underweight | — | $10.05 | $9.77 | -2.8% | -2.9% | -2.0% | -2.0% | -3.3% | -1.4% |
| Apr 25 | Barclays | Downgrade | Overweight → Equal Weight | — | $9.33 | $9.30 | -0.3% | -1.6% | -2.5% | -0.8% | +0.0% | +0.3% |
| Apr 24 | Barclays | Downgrade | Overweight → Equal Weight | — | $9.65 | $9.52 | -1.3% | -3.3% | -4.9% | -5.7% | -4.0% | -3.3% |
| Feb 28 | Barclays | Maintains | Overweight → Overweight | — | $11.20 | $11.29 | +0.8% | +1.8% | +1.0% | -0.6% | -0.6% | -3.0% |
| Feb 17 | BMO Capital | Downgrade | Outperform → Market Perform | — | $11.65 | $11.53 | -1.0% | +0.3% | -1.3% | -1.4% | -0.9% | -1.2% |
| Feb 1 | Barclays | Maintains | Overweight → Overweight | — | $12.16 | $12.06 | -0.8% | +0.8% | +0.2% | +0.2% | -0.9% | -0.4% |
| Jan 27 | Jefferies | Upgrade | Hold → Buy | — | $11.64 | $11.90 | +2.2% | +2.1% | +2.6% | +4.5% | +5.3% | +4.7% |
| Nov 15 | JP Morgan | Maintains | Neutral → Neutral | — | $11.56 | $11.66 | +0.9% | -2.1% | -4.2% | -5.2% | -4.8% | -4.1% |
| Nov 10 | UBS | Upgrade | Sell → Neutral | — | $10.83 | $11.15 | +3.0% | +4.7% | +5.6% | +6.7% | +4.5% | +2.3% |
| Nov 8 | Piper Sandler | Upgrade | Underweight → Neutral | — | $10.97 | $11.01 | +0.4% | +1.2% | -1.3% | +3.4% | +4.3% | +5.4% |
| Oct 25 | Barclays | Maintains | Overweight → Overweight | — | $9.53 | $9.48 | -0.5% | +2.6% | +4.6% | +3.6% | +5.7% | +6.3% |
| Oct 21 | Jefferies | Maintains | Hold → Hold | — | $9.34 | $9.28 | -0.6% | +0.4% | +2.0% | +4.7% | +6.7% | +5.7% |
| Aug 9 | BMO Capital | Maintains | Outperform → Outperform | — | $10.09 | $10.03 | -0.6% | +3.7% | +6.7% | +8.6% | +10.3% | +10.1% |
| Jun 14 | UBS | Maintains | Sell → Sell | — | $10.77 | $10.73 | -0.4% | -4.2% | -0.7% | -4.5% | -2.9% | -1.6% |
| May 12 | Goldman Sachs | Maintains | Neutral → Neutral | — | $10.39 | $10.41 | +0.2% | +4.4% | +6.6% | +7.2% | +10.4% | +8.5% |
| May 10 | Piper Sandler | Downgrade | Neutral → Underweight | — | $10.48 | $10.38 | -1.0% | -0.2% | -0.9% | +3.5% | +5.7% | +6.3% |
| Mar 16 | Piper Sandler | Maintains | Neutral → Neutral | — | $9.96 | $10.11 | +1.5% | +4.3% | +6.8% | +7.0% | +8.1% | +8.9% |
| Mar 10 | Citigroup | Maintains | Neutral → Neutral | — | $10.28 | $10.06 | -2.1% | -1.6% | -2.5% | -4.6% | -3.1% | +1.1% |
| Mar 1 | BofA Securities | Downgrade | Buy → Neutral | — | $11.01 | $11.16 | +1.4% | -7.8% | -4.8% | -5.4% | -7.4% | -10.3% |
| Mar 1 | Raymond James | Downgrade | Outperform → Market Perform | — | $11.01 | $11.16 | +1.4% | -7.8% | -4.8% | -5.4% | -7.4% | -10.3% |
| Jun 15 | Citigroup | Maintains | Neutral → Neutral | — | $15.63 | $15.61 | -0.1% | -2.1% | -2.6% | -6.1% | -8.8% | -8.2% |
| Mar 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $13.91 | $14.05 | +1.0% | +1.1% | +1.4% | +3.2% | +5.5% | +4.5% |
| Mar 8 | Goldman Sachs | Downgrade | Buy → Neutral | — | $13.91 | $13.76 | -1.1% | -0.6% | +0.0% | +1.1% | +1.4% | +3.2% |
| Mar 2 | JP Morgan | Downgrade | Overweight → Neutral | — | $14.72 | $14.55 | -1.2% | -2.9% | -5.7% | -7.7% | -5.5% | -6.0% |
| Feb 23 | Raymond James | Maintains | Outperform → Outperform | — | $15.50 | $15.74 | +1.5% | -1.8% | -1.3% | -2.9% | -4.2% | -5.0% |
| Jan 25 | Raymond James | Maintains | Outperform → Outperform | — | $17.43 | $17.26 | -1.0% | -1.1% | -2.0% | -3.3% | -1.4% | -2.5% |
No insider trades available.
8-K · 8.01
!! High
Viatris Inc. -- 8-K 8.01: Material Event / Announcement
Viatris will discuss Q1 2026 financial results via conference call today, providing investors with updated earnings performance and guidance.
May 7
8-K · 8.01
!! High
Viatris Inc. -- 8-K 8.01: Material Event / Announcement
Viatris will hold an earnings call today at 8:30 a.m. ET to discuss Q4 and full-year 2025 financial results, providing investors opportunity to hear management commentary and guidance.
Feb 26
8-K
Viatris Inc. -- 8-K Filing
Viatris Inc. filed an 8-K that indicates the company meets emerging growth company criteria under SEC regulations, potentially offering regulatory relief and disclosure accommodations for the pharmaceutical manufacturer.
Feb 3
Data updated apr 27, 2026 8:27am
· Source: massive.com